British drugmaker GSK announced on Wednesday that the Chinese Medicines Agency has approved its monoclonal antibody Nucala for the treatment of severe asthma.

The green light is for the maintenance treatment of severe eosinophilic asthma in adults and adolescents over the age of 12, the company said in a press release.

GSK points out that nearly 46 million adults suffer from asthma in China, of whom around 6% are affected by a severe form of the disease.

Nucala is already approved in the United States, Europe and more than 25 other countries in this indication.

Copyright (c) 2024 CercleFinance.com. All rights reserved.